Granules India surges as its arm receives VAI classification for Telangana facility
Granules India is currently trading at Rs. 634.20, up by 13.05 points or 2.10% from its previous closing of Rs. 621.15 on the BSE.
The scrip opened at Rs. 625.35 and has touched a high and low of Rs. 638.50 and Rs. 625.00 respectively. So far 30045 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 640.00 on 25-Mar-2026 and a 52 week low of Rs. 412.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 640.00 and Rs. 600.25 respectively. The current market cap of the company is Rs. 15701.65 crore.
The promoters holding in the company stood at 38.82%, while Institutions and Non-Institutions held 31.03% and 30.15% respectively.
Granules India’s wholly owned subsidiary -- Granules Life Sciences (GLS) has concluded a recent US FDA inspection of its manufacturing facility at Shamirpet, Telangana, with an inspection classification of Voluntary Action Indicated (VAI).
The Establishment Inspection Report (EIR) was issued following a current Good Manufacturing Practice (cGMP) and pre-approval inspection (PAI) of the oral solid dosage manufacturing operations conducted between December 15 and 19, 2025. The inspection is now closed, and no regulatory action has been recommended. This development further strengthens Granules India’s finished dosage manufacturing capabilities by enabling multi-site manufacturing for the approved products.
